[PDF][PDF] Safety and Effectiveness of Molnupiravir (LAGEVRIO Ò) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
MKAWY Yanagida, DKS Maekawa - 2023 - scienceopen.com
Introduction: Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious diseases and …, 2023 - Springer
Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
S Shinozaki, A Watanabe, M Kimata… - Infectious Diseases and …, 2024 - Springer
Methods The surveillance data were collected from December 27, 2021, to May 2, 2023. All
reported adverse events were collected for safety analysis. Adverse drug reactions (ADRs) …
reported adverse events were collected for safety analysis. Adverse drug reactions (ADRs) …
[PDF][PDF] Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry. Antibiotics …
T Lupia, S Corcione, N Shbaklo, L Boglione… - 2022 - academia.edu
Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …
Real-life experience of molnupiravir in hospitalized patients who developed SARS-CoV2-infection: preliminary results from CORACLE registry
T Lupia, S Corcione, N Shbaklo, L Boglione… - Antibiotics, 2022 - mdpi.com
Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …
Safety profile of molnupiravir in the treatment of COVID-19: A descriptive study based on FAERS data
G Santi Laurini, N Montanaro, D Motola - Journal of Clinical Medicine, 2022 - mdpi.com
Concerns have been raised about the actual benefit and safety of molnupiravir, a new
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …
Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19
Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
What will be the role of molnupiravir in the treatment of COVID-19 infection?
A Vitiello, V Troiano, R La Porta - Drugs & Therapy Perspectives, 2021 - Springer
The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
A Phase 1 Study of Molnupiravir, The First Approved Oral COVID-19 Therapy, in Japanese Healthy Participants: Pharmacokinetics
長谷川千尋 - 日本臨床薬理学会学術総会抄録集第43 回日本臨床 …, 2022 - jstage.jst.go.jp
[Objective] Molnupiravir (MOV) is a prodrug of the ribonucleoside analog, N-hydroxycytidine
(NHC), that inhibits replication of RNA viruses including SARS-CoV-2 and is the first …
(NHC), that inhibits replication of RNA viruses including SARS-CoV-2 and is the first …
[引用][C] A Phase 1, Randomized, Placebo-Controlled Study of Molnupiravir in Healthy Japanese to Support Special Approval in Japan to Treat COVID-19
中村圭介 - 2022 - ci.nii.ac.jp
CiNii 博士論文 - A Phase 1, Randomized, Placebo-Controlled Study of Molnupiravir in Healthy
Japanese to Support Special Approval in Japan to Treat COVID-19 CiNii 国立情報学研究所 …
Japanese to Support Special Approval in Japan to Treat COVID-19 CiNii 国立情報学研究所 …